BioSpace News Archive

Masimo Corporation (Nasdaq: MASI) today announced its financial results for the first quarter ended March 30, 2024.

McKesson Corporation (NYSE: MCK) has released its fiscal 2024 fourth quarter financial results.

Biote (NASDAQ: BTMD), a leading solutions provider in preventive health care through the delivery of personalized hormone optimization and therapeutic wellness, today announced financial results for the first quarter ended March 31, 2024.

According to recent study by nova one advisor, the U.S. Preclinical CRO market size was valued at USD 3.19 billion in 2023 and is anticipated to reach around USD 6.39 billion by 2033, growing at a CAGR of 7.2 % from 2024 to 2033.

DBV Technologies reported financial results for the first quarter 2024.

Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE) today announced that Eric Crombez, M.D., the company’s chief medical officer and executive vice president, will participate in a fireside at Bank of America’s 2024 Healthcare Conference on Tuesday, May 14, 2024, at 1:40 p.m. PT.

Jasper Therapeutics, Inc. announced that its management will present at the following upcoming investor conferences in May.

DURECT Corporation, a late-stage biopharmaceutical company pioneering the development of epigenetic therapies to transform the treatment of serious and life-threatening conditions, including acute organ injury and cancer, announced that the company will report its first quarter financial results on Monday, May 13, 2024.

Bio-Rad Laboratories, Inc. (NYSE: BIO and BIO.B), a global leader in life science research and clinical diagnostics products, today announced financial results for the first quarter ended March 31, 2024.

Vera Therapeutics, Inc. announced that on May 1, 2024, the Compensation Committee of Vera’s Board of Directors granted inducement awards consisting of non-qualified stock options to purchase 15,000 shares of Class A common stock and restricted stock units for 7,500 shares of Class A common stock to three new employees under Vera’s 2024 Inducement Plan.